Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population

Pinpathomrat, N; Intapiboon, P; Seepathomnarong, P; Ongarj, J; Sophonmanee, R; Hengprakop, J; Surasombatpattana, S; Uppanisakorn, S; Mahasirimongkol, S; Sawaengdee, W; Phumiamorn, S; Sapsutthipas, S; Kongkamol, C; Ingviya, T; Sangsupawanich, P; Chusri, S

COVID-19 Collection

Journal article

Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population

Abstract:: Objectives: The aim of this study was to assess the safety and immunogenicity of a dose-sparing fractional intradermal (ID) booster strategy with the mRNA-1273 COVID-19 vaccine. Methods: COVID-19 naive adults aged 18e30 years were recruited from a previous study on primary vaccination regimens that compared 20 mg ID vaccinations with 100 mg intramuscular (IM) vaccinations with mRNA-1273 as the primary vaccination series. Participants previously immunized with ID regimens were randomly assigned (1:1) to receive a fractional ID booster dose (20 mg) or the standard-of-care intramuscular (IM) booster dose (50 mg) of the mRNA-1273 vaccine, 6 months after completing their primary series (ID-ID and ID-IM group, respectively). Participants that had received a full dose IM regimen as the primary series, received the IM standard-of-care booster dose (IM-IM group). In addition, COVID-19 naive individuals aged 18e40 years who had received an IM mRNA vaccine as the primary series were recruited from the general population to receive a fractional ID booster dose (IM-ID group). Immunogenicity was assessed using IgG anti-spike antibody responses and neutralizing capacity against SARS-CoV-2. Cellular immune responses were measured in a sub-group. Safety and tolerability were monitored. Results: In January 2022, 129 participants were included in the study. Fractional ID boosting was safe and well tolerated, with fewer systemic adverse events compared with IM boosting. At day 28 post-booster, anti-spike S1 IgG geometric mean concentrations were 9106 (95% CI, 7150e11 597) binding antibody units (BAU)/mL in the IM-IM group and 4357 (3003e6322) BAU/mL; 6629 (4913e8946) BAU/mL; and 5264 (4032e6873) BAU/mL in the ID-IM, ID-ID, and IM-ID groups, respectively. Discussion: Intradermal boosting provides robust immune responses and is a viable dose-sparing strategy for mRNA COVID-19 vaccines. The favourable side-effect profile supports its potential to reduce vaccine hesitancy. Fractional dosing strategies should be considered early in the clinical development of future mRNA vaccines to enhance vaccine availability and pandemic preparedness.Immunogenetics and cellular immunology of bacterial infectious disease

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Pinpathomrat, N., Intapiboon, P., Seepathomnarong, P., Ongarj, J., Sophonmanee, R., Hengprakop, J., Surasombatpattana, S., Uppanisakorn, S., Mahasirimongkol, S., Sawaengdee, W., Phumiamorn, S., Sapsutthipas, S., Kongkamol, C., Ingviya, T., Sangsupawanich, P., & Chusri, S. (2022). Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population. Npj Vaccines, 7(1), 52–52.

MLA Style

Pinpathomrat, N, et al. “Immunogenicity and Safety of an Intradermal ChAdOx1 NCoV-19 Boost in a Healthy Population.” Npj Vaccines, vol. 7, no. 1, 2022, pp. 52–52.

Chicago Style

Pinpathomrat, N, P Intapiboon, P Seepathomnarong, et al. 2022. “Immunogenicity and Safety of an Intradermal ChAdOx1 NCoV-19 Boost in a Healthy Population.” Npj Vaccines 7 (1): 52–52.
Print